All In Biotech

Drug Trial Radar · NCT07869953

Oftac Eye Drops (0.05% Tacrolimus Ophthalmic Emulsion) for the Treatment of Active Non-infectious Anterior Uveitis

A Multicenter, Open Label Phase-1/2a Study of Oftac Eye Drops in Active Non-Infectious Anterior Uveitis Patients

Last checked: Nov 20, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Mar 7, 2024

Primary completion

Mar 25, 2025

Study completion Mar 25, 2025

Sponsor

Lead sponsor
BioNanoSim Ltd.Industry
Sponsor type
Industry
First posted
Oct 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to assess the safety and tolerability of Oftac in active non-infectious anterior uveitis patients. The main questions it aims to answer are: 1. Are adverse events observed during the treatment period and if so, what are their severity? 2. What is the change in Best Corrected Visual Acuity (BCVA) test using the Early Treatment Diabetic Retinopathy Study (ETDRS) acuity chart from baseline to Day 29? 3. What is the change in Intraocular Pressure (IOP) from baseline to Day 29? The expected study duration for each patient will be up to 6 weeks including up to 1 week for screening, a 4-week treatment period and a 1-week safety follow-up period. Patients will be administered Oftac 0.05% eye drops four (4) times every day, for up to six weeks.

Conditions

  • Non-Infectious Anterior Uveitis

Interventions

  • Oftac: 0.05% tacrolimus ophthalmic emulsionDrug

    Oftac 0.05% eye drops administered as a single drop four (4) times every day (QID) as a monotherapy in patients not currently being administered another treatment, or as an add-on therapy to an existing therapeutic regimen.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse eventsTime frame: 6 weeks
  2. Change in Best Corrected Visual Acuity (BCVA)Time frame: 6 weeks
  3. Change in Intraocular Pressure (IOP)Time frame: 6 weeks

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Department of Ophthalmology, Soroka University Medical Center, Ben-Gurion University of the Negev

    Beersheba, Israel

  • Department of Ophthalmology, Bnai Zion Medical Center

    Haifa, Israel

  • Department of Ophthalmology, Carmel Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology

    Haifa, Israel

  • Department of Ophthalmology, Rambam Medical Center, The Ruth and Bruce Rappaport Faculty of Medicine, Technion, Israel Institute of Technology

    Haifa, Israel

  • Department of Ophthalmology, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem

    Jerusalem, Israel

  • Department of Ophthalmology, Rabin Medical Center

    Petah Tikva, Israel

  • Shamir Medical Center

    Tsrifin, Israel

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.